T cell primary proliferative response to antigens and mitogen in patients with multiple sclerosis: Assessment of an immunosuppressive treatment with mitoxantrone

G. Ristori, M. Salvetti, M. Falcone, P. Fiori, C. Buttinelli, E. Millefiorini, C. Pozzilli

Research output: Contribution to journalArticlepeer-review

Abstract

To investigate the use of T cell reactivity in evaluating the effect of immunosuppressive treatments in Multiple Sclerosis (MS), we studied the T cell primary proliferative response to myelin basic protein, PPD and phytohemagglutinin in 6 relapsing-remitting patients, included in a placebo-controlled trial of mitoxantrone (MX). Blood collection, clinical evaluation and Gd-enhanced MRI were performed (on the same day) before and after two months of treatment. No decrease of antigen and mitogen stimulation indexes after therapy was observed in both MX and placebo treated patients. Accordingly, no difference between the two groups was evident comparing leucocyte counts before and after therapy. The negative result may be due to the posology of drug employed in the clinical trial. The use of T cell primary response to antigens, including putative autoantigens, and mitogen, may represent a functional approach to the assessment of immunosuppressant and immunomodulatory drugs in MS patients.

Original languageEnglish
Pages (from-to)137-138
Number of pages2
JournalEOS Rivista di Immunologia ed Immunofarmacologia
Volume14
Issue number3-4
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'T cell primary proliferative response to antigens and mitogen in patients with multiple sclerosis: Assessment of an immunosuppressive treatment with mitoxantrone'. Together they form a unique fingerprint.

Cite this